MA45793A - Composés et procédés de stimulation de la myélinisation - Google Patents

Composés et procédés de stimulation de la myélinisation

Info

Publication number
MA45793A
MA45793A MA045793A MA45793A MA45793A MA 45793 A MA45793 A MA 45793A MA 045793 A MA045793 A MA 045793A MA 45793 A MA45793 A MA 45793A MA 45793 A MA45793 A MA 45793A
Authority
MA
Morocco
Prior art keywords
myelination
methods
stimulation compounds
stimulation
compounds
Prior art date
Application number
MA045793A
Other languages
English (en)
Inventor
Drew Adams
Dharmaraja Allimuthu
Matthew Elitt
Zita Hubler
Steven B Landau
Paul Tesar
Original Assignee
Univ Case Western Reserve
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Case Western Reserve filed Critical Univ Case Western Reserve
Publication of MA45793A publication Critical patent/MA45793A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychiatry (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
MA045793A 2016-07-27 2017-07-27 Composés et procédés de stimulation de la myélinisation MA45793A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662367416P 2016-07-27 2016-07-27
US201762452204P 2017-01-30 2017-01-30

Publications (1)

Publication Number Publication Date
MA45793A true MA45793A (fr) 2021-03-24

Family

ID=61017363

Family Applications (2)

Application Number Title Priority Date Filing Date
MA045793A MA45793A (fr) 2016-07-27 2017-07-27 Composés et procédés de stimulation de la myélinisation
MA053246A MA53246A (fr) 2016-07-27 2017-07-27 Composés et procédés pour favoriser la myélinisation

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA053246A MA53246A (fr) 2016-07-27 2017-07-27 Composés et procédés pour favoriser la myélinisation

Country Status (7)

Country Link
US (3) US11344511B2 (fr)
EP (2) EP3838287A3 (fr)
JP (2) JP7325104B2 (fr)
CN (2) CN109789128A (fr)
CA (1) CA3031818A1 (fr)
MA (2) MA45793A (fr)
WO (1) WO2018022904A2 (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA45793A (fr) 2016-07-27 2021-03-24 Univ Case Western Reserve Composés et procédés de stimulation de la myélinisation
CN109803662A (zh) * 2016-08-12 2019-05-24 加利福尼亚大学董事会 髓鞘再生疗法
CN109512817A (zh) * 2017-09-20 2019-03-26 中国人民解放军陆军总医院 氯马斯汀或其组合物的制药用途
US10918610B2 (en) 2017-12-22 2021-02-16 Case Western Reserve University Compounds and methods of promoting myelination
WO2019204411A1 (fr) * 2018-04-17 2019-10-24 Case Western Reserve University Composés et procédés de promotion de la myélinisation
US20210163888A1 (en) * 2018-04-17 2021-06-03 Case Western Reserve University Induction of myelinating oligodendrocytes in human cortical spheroids
JP2022036341A (ja) * 2018-10-12 2022-03-08 学校法人慶應義塾 慢性皮膚炎の治療のための医薬組成物
US20220024851A1 (en) * 2018-12-03 2022-01-27 Convelo Therapeutics, Inc. Crystalline forms of multicyclic compounds and uses thereof
EP3797769A1 (fr) 2019-09-25 2021-03-31 Fontès, M. Michel Composition a usage therapeutique
EP3831369A1 (fr) * 2019-12-03 2021-06-09 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Squalène pour le traitement des troubles de démyélinisation
JP2021143141A (ja) * 2020-03-11 2021-09-24 花王株式会社 制御性ｔ細胞誘導剤
CN111440771A (zh) * 2020-03-17 2020-07-24 中山大学附属第三医院 一种含有clcn2纯合突变的白质脑病患者特异诱导多能干细胞系
EP4143303A4 (fr) * 2020-05-01 2024-09-04 The Children's Medical Center Corporation Compositions et méthodes pour favoriser la myélinisation
WO2021235848A1 (fr) * 2020-05-20 2021-11-25 고려대학교 산학협력단 Procédé de préparation d'organoïdes comprenant des oligodendrocytes à partir de cellules souches neurales spécialisées pour la différenciation en oligodendrocytes, organoïde préparé par le procédé, et leur utilisation
WO2021241504A1 (fr) 2020-05-25 2021-12-02 小野薬品工業株式会社 Agent permettant de protéger et/ou de régénérer des jonctions neuromusculaires
US20240167030A1 (en) * 2021-04-02 2024-05-23 Case Western Reserve University Methods and compositions for accelerating oligodendrocyte maturation
CN113584041A (zh) * 2021-04-15 2021-11-02 浙江警察学院 一种转基因斑马鱼(mbp:egfp)脱脊髓疾病模型的构建方法
CN113616657B (zh) * 2021-08-02 2022-12-20 中山大学·深圳 化合物在制备治疗和/或预防脱髓鞘疾病药物的应用
CN113603732B (zh) * 2021-08-25 2024-02-13 江南大学 一种非动物源硫酸软骨素寡糖及其制备方法
CN114651787A (zh) * 2022-04-21 2022-06-24 贵州医科大学附属医院 用于构建小鼠视神经特异性脱髓鞘模型的小鼠的构建方法及其应用
EP4525841A1 (fr) * 2022-05-18 2025-03-26 The Scripps Research Institute Procédé d'amélioration synergique de remyélinisation par modulation de rxr et d'un partenaire hétérodimère
AR129912A1 (es) * 2022-07-15 2024-10-09 Biogen Ma Inc Inhibidores de proteína de unión a emopamil y usos de estos
CN119998288A (zh) * 2022-09-30 2025-05-13 基因泰克公司 胆固醇生物合成的乙内酰脲调节剂及其用于促进髓鞘再生的用途

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4904582A (en) 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
FR2641276B1 (fr) 1988-12-30 1991-07-12 Sanofi Sa Derives du benzene, leur preparation et les compositions pharmaceutiques en contenant
AU704601B2 (en) 1994-01-18 1999-04-29 Scripps Research Institute, The Zinc finger protein derivatives and methods therefor
US6140466A (en) 1994-01-18 2000-10-31 The Scripps Research Institute Zinc finger protein derivatives and methods therefor
USRE39229E1 (en) 1994-08-20 2006-08-08 Gendaq Limited Binding proteins for recognition of DNA
GB9824544D0 (en) 1998-11-09 1999-01-06 Medical Res Council Screening system
US5789538A (en) 1995-02-03 1998-08-04 Massachusetts Institute Of Technology Zinc finger proteins with high affinity new DNA binding specificities
US5925523A (en) 1996-08-23 1999-07-20 President & Fellows Of Harvard College Intraction trap assay, reagents and uses thereof
GB9710807D0 (en) 1997-05-23 1997-07-23 Medical Res Council Nucleic acid binding proteins
GB9710809D0 (en) 1997-05-23 1997-07-23 Medical Res Council Nucleic acid binding proteins
KR20000021073A (ko) 1998-09-25 2000-04-15 박원배 콜레스테롤 생합성 저해제
US6140081A (en) 1998-10-16 2000-10-31 The Scripps Research Institute Zinc finger binding domains for GNN
GB9824207D0 (en) 1998-11-04 1998-12-30 Zeneca Ltd Neurological disorders
KR20000042507A (ko) 1998-12-21 2000-07-15 박원배 콜레스테롤 생합성 저해효과를 나타내는 디벤조[a,g]퀴놀리지늄 유도체
US6534261B1 (en) 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US6453242B1 (en) 1999-01-12 2002-09-17 Sangamo Biosciences, Inc. Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites
FR2794742B1 (fr) 1999-06-11 2005-06-03 Sanofi Synthelabo Nouveaux derives du benzene, un procede pour leur preparation et les compositions pharmaceutiques les contenant
US20020061512A1 (en) 2000-02-18 2002-05-23 Kim Jin-Soo Zinc finger domains and methods of identifying same
AU2001253255A1 (en) 2000-04-07 2001-10-23 Large Scale Biology Corporation Compositions and methods for inhibiting gene expression
WO2001088197A2 (fr) 2000-05-16 2001-11-22 Massachusetts Institute Of Technology Methodes et compositions de dosage de piegeage par interaction
JP2002060786A (ja) 2000-08-23 2002-02-26 Kao Corp 硬質表面用殺菌防汚剤
GB0108491D0 (en) 2001-04-04 2001-05-23 Gendaq Ltd Engineering zinc fingers
EP1421177A4 (fr) 2001-08-20 2006-06-07 Scripps Research Inst Domaines de fixation en doigt de zinc pour cnn
JP4567448B2 (ja) 2002-07-17 2010-10-20 レツク・フアーマシユーテイカルズ・デー・デー コレステロール生合成の阻害剤としての新規なピリジルエタノール（フェニルエチル）アミン誘導体、その調製方法、および新規な誘導体を含有する医薬組成物
CA2607598A1 (fr) 2005-06-06 2006-12-14 University Of South Florida Traitement par agonistes du recepteur sigma apres un accident vasculaire cerebral
US20080089861A1 (en) 2006-07-10 2008-04-17 Went Gregory T Combination therapy for treatment of demyelinating conditions
WO2008021970A2 (fr) * 2006-08-09 2008-02-21 Reid William K Traitement d'une maladie des motoneurones, incluant certains troubles neurologiques, des neuropathies motrices et des maladies inflammatoires chroniques
WO2008124131A1 (fr) * 2007-04-05 2008-10-16 The John Hopkins University Agents antifongiques comme neuroprotecteurs
US8585526B2 (en) 2007-06-18 2013-11-19 American Axle & Manufacturing, Inc. Vehicle driveline component having heat sink for increased heat rejection capabilities
US20100009970A1 (en) * 2008-03-19 2010-01-14 Combinatorx (Singapore) Pte. Ltd. Compositions and methods for treatment of viral diseases
US20100092479A1 (en) * 2008-08-18 2010-04-15 Combinatorx (Singapore) Pte. Ltd. Compositions and methods for treatment of viral diseases
US20100183613A1 (en) * 2008-10-22 2010-07-22 Novartis Ag Methods of using mevalonate decarboxylase (mvd) antagonists
US8586526B2 (en) 2010-05-17 2013-11-19 Sangamo Biosciences, Inc. DNA-binding proteins and uses thereof
US9856233B2 (en) * 2013-09-10 2018-01-02 Board Of Regents Of The University Of Texas System Therapeutics targeting truncated adenomatous polyposis coli (APC) proteins
WO2015088625A2 (fr) * 2013-09-25 2015-06-18 Case Western Reserve University Composés et procédés pour favoriser la myélinisation
WO2015048306A1 (fr) * 2013-09-26 2015-04-02 The Scripps Research Institute Nouveaux agents ciblant cyp51
WO2015143072A1 (fr) * 2014-03-18 2015-09-24 Whitehead Institute For Biomedical Research Procédés pour inhiber la prolifération de cellules cancéreuses et utilisations associées
US10082496B2 (en) * 2014-09-10 2018-09-25 Board Of Regents Of The University Of Texas System Targeting emopamil binding protein (EBP) with small molecules that induce an abnormal feedback response by lowering endogenous cholesterol biosynthesis
MA45793A (fr) 2016-07-27 2021-03-24 Univ Case Western Reserve Composés et procédés de stimulation de la myélinisation
US10918610B2 (en) 2017-12-22 2021-02-16 Case Western Reserve University Compounds and methods of promoting myelination

Also Published As

Publication number Publication date
CN109789128A (zh) 2019-05-21
EP3838287A3 (fr) 2021-07-28
US20180228743A1 (en) 2018-08-16
WO2018022904A3 (fr) 2019-02-14
CN114652735A (zh) 2022-06-24
US20230000798A1 (en) 2023-01-05
US12403104B2 (en) 2025-09-02
WO2018022904A2 (fr) 2018-02-01
US11344511B2 (en) 2022-05-31
MA53246A (fr) 2021-07-28
CA3031818A1 (fr) 2018-02-01
JP2023139105A (ja) 2023-10-03
EP3490556A2 (fr) 2019-06-05
EP3490556A4 (fr) 2020-04-15
JP7325104B2 (ja) 2023-08-14
US20190269670A1 (en) 2019-09-05
JP2019525938A (ja) 2019-09-12
EP3838287A2 (fr) 2021-06-23

Similar Documents

Publication Publication Date Title
MA45793A (fr) Composés et procédés de stimulation de la myélinisation
EP3359168A4 (fr) Composés thérapeutiques et procédés
IL284172A (en) Diagnostic methods for t cell therapy
EP3380101A4 (fr) Composés inhibiteurs d'eif4-a et procédés associés
EP3350508A4 (fr) Lucarne artificielle et procédés
DK3394094T3 (da) T-celle receptorer specifikke for ny-eso-1 tumor antigen-hla-a*02 komplekset
EP3349753A4 (fr) Composés antifongiques et procédés de préparation
PL3618545T3 (pl) Sposoby zapewniające przyznania UL zawierające konfigurację dziedziny czasu
EP3373906A4 (fr) Compositions et procédés destinés à une application sur la peau
EP3331612A4 (fr) Procédés et compositions destinés à la thérapie de tumeurs
BR112017011769A2 (pt) treinamento de músculo oral
EP4141374C0 (fr) Ensemble chargeur à tambour et procédés
EP3341074A4 (fr) Ensemble de stimulation implantable
EP3443094A4 (fr) Procédés de réduction de l'expression de c9orf72
EP3733242C0 (fr) L'assurance qualité de radiothérapie
MA39915B1 (fr) Composés de pladiénolide pyridine et leurs procédés d'utilisation
HUE050944T2 (hu) Kezelési eljárás tradipitant alkalmazásával
EP3426262A4 (fr) Agents de réticulation et procédés associés
PL3393468T3 (pl) Metody leczenia niedoboru odporności
EP3503733C0 (fr) Composés et compositions insectifuges et procédés associés
EP3433587A4 (fr) Balance et procédés associés
EP3347003A4 (fr) Composés de thréonate et leurs procédés d'utilisation
EP3259254A4 (fr) Composés thérapeutiques
EP3453088A4 (fr) Chemin de câbles optimisé et procédés
EP3320329A4 (fr) Composés de détection et procédés et dispositifs associés